{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:56:33Z","timestamp":1788393393256,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/00789"],"award-info":[{"award-number":["PI21\/00789"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["INT22\/00066"],"award-info":[{"award-number":["INT22\/00066"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.lungcan.2025.108545","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:59:03Z","timestamp":1744894743000},"page":"108545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma"],"prefix":"10.1016","volume":"203","author":[{"given":"Ernest","family":"Nadal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-8366","authenticated-orcid":false,"given":"Paloma","family":"Mart\u00edn-Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"Ben\u00edtez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria \u00c1ngeles","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Cedr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-434X","authenticated-orcid":false,"given":"Manuel","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-1853","authenticated-orcid":false,"given":"Elia","family":"Sais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-5388","authenticated-orcid":false,"given":"Maria","family":"Saig\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-4710","authenticated-orcid":false,"given":"Rafael","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Vil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartomeu","family":"Massut\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Mesas-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-6170","authenticated-orcid":false,"given":"Amelia","family":"Insa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Plans-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hijazo-Pechero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mu\u00f1oz-Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-3319","authenticated-orcid":false,"given":"Jes\u00fas","family":"Brenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108545_b0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.lungcan.2025.108545_b0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0015","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lungcan.2025.108545_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000461","article-title":"Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma","volume":"8","author":"Hotta","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.lungcan.2025.108545_b0030","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1080\/21645515.2021.1917933","article-title":"Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma","volume":"17","author":"Metro","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lungcan.2025.108545_b0035","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.21037\/tlcr.2020.01.08","article-title":"Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma","volume":"9","author":"Woodard","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2025.108545_b0040","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-018-0145-3","article-title":"Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma","volume":"119","author":"Xu","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2025.108545_b0050","doi-asserted-by":"crossref","first-page":"21357","DOI":"10.1038\/s41598-021-00831-4","article-title":"Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort","volume":"11","author":"Cedres","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.lungcan.2025.108545_b0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108545_b0060","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0065","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108545_b0070","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3390\/cancers12113099","article-title":"Transforming Growth Factor-\u03b2: A Multifunctional Regulator of Cancer Immunity","volume":"12","author":"Xue","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2025.108545_b0075","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41417-023-00638-7","article-title":"Small extracellular vesicle TGF-\u03b2 in cancer progression and immune evasion","volume":"30","author":"Hosseini","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.lungcan.2025.108545_b0080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85974","article-title":"TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.lungcan.2025.108545_b0085","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2023.41.16_suppl.8506","article-title":"Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma","volume":"41","author":"Fennell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920962362","article-title":"PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study","volume":"12","author":"Jin","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"e000433","key":"10.1016\/j.lungcan.2025.108545_b0095","article-title":"Dual targeting of TGF-\u03b2 and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.lungcan.2025.108545_b0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.lungcan.2025.108545_b0105","unstructured":"World Medical Association. Declaration Of Helsinki. Ethical Principles for Medical Research Involving Human Subjects 2013. https:\/\/www.wma.net\/what-we-do\/medical-ethics\/declaration-of-helsinki\/ (accessed February 26, 2024)."},{"key":"10.1016\/j.lungcan.2025.108545_b0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2020.06.034","article-title":"Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group","volume":"147","author":"Remon","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108545_b0115","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108545_b0130","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0135","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1\u2013high advanced NSCLC: A randomized, open-label, phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2025.108545_b0140","article-title":"Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2\/3 trial","author":"Oh","year":"2024","journal-title":"Hepatology"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:26:36Z","timestamp":1777782396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"alternative-id":["S0169500225004374"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108545","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108545"}}